Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF

PURPOSE: Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with line...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Smith, B. Douglas, Jones, Richard J., Cho, Eunpi, Kowalski, Jeanne, Karp, Judith E., Gore, Steven D., Vala, Milada, Meade, Brooke, Baker, Sharyn D., Zhao, Ming, Piantadosi, Steven, Zhang, Zhe, Blumenthal, Gideon, Warlick, Erica D., Brodsky, Robert A., Murgo, Anthony, Rudek, Michelle A., Matsui, William H.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2010
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033102/
https://ncbi.nlm.nih.gov/pubmed/20598742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2010.06.001
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة